Scientists test 'Living Drug' with emergency off switch for tough childhood cancers
NCT ID NCT03721068
Summary
This early-stage study is testing a new type of personalized cell therapy for children and young adults whose neuroblastoma or osteosarcoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better find and attack cancer cells, and then infuse them back into the patient. The modified cells include a built-in 'off switch' to stop treatment if severe side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory - Winship Cancer Institute
WITHDRAWNAtlanta, Georgia, 30322, United States
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599-7295, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.